Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

Be­fore any drug is of­fi­cial­ly proven ef­fec­tive against Covid-19, every da­ta nugget sur­round­ing an ex­per­i­men­tal treat­ment un­der­stand­ably arous­es in­vestors’ and pa­tients’ hopes alike. Thurs­day night …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.